Use of bortezomib for prevention and treatment of rejection in sensitized patients. Academic Article uri icon

Overview

MeSH Major

  • Boronic Acids
  • Graft Rejection
  • Isoantibodies
  • Kidney Transplantation
  • Protease Inhibitors
  • Pyrazines

abstract

  • We report 2 cases of sensitized patients who were successfully treated with bortezomib therapy resulting in reduction of donor-specific antibodies (DSA). Our cases illustrate the synergistic effects of combination therapy that includes bortezomib on prevention and treatment of AMR in highly sensitized patients. Moving forward, long-term data on sensitized patients treated with bortezomib are needed to fully evaluate the impact of this therapy.

publication date

  • December 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 20524323

Additional Document Info

start page

  • 499

end page

  • 503